Ainos (AIMD) & Its Peers Financial Review

Ainos (NASDAQ:AIMD) is one of 1,000 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Ainos to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Ainos and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	0	0	0	0	N/A
Ainos Competitors	6394	18740	44698	917	2.57

As a group, “Pharmaceutical preparations” companies have a potential upside of 84.06%. Given Ainos’ peers higher possible upside, analysts clearly believe Ainos has less favorable growth aspects than its peers.

Risk & Volatility

Ainos has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Ainos’ peers have a beta of 1.09, indicating that their average share price is 9% more volatile than the S&P 500.

Insider & Institutional Ownership

44.7% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 4.6% of Ainos shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Ainos and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Ainos	$120,000.00	-$13.77 million	-0.41
Ainos Competitors	$1.68 billion	$146.16 million	-1.65

Ainos’ peers have higher revenue and earnings than Ainos. Ainos is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Ainos and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ainos	-11,205.49%	-47.96%	-40.37%
Ainos Competitors	-2,459.06%	-249.83%	-30.60%

Summary

Ainos peers beat Ainos on 7 of the 10 factors compared.

Ainos Company Profile

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.